Compounded Glutathione Is in Danger
What’s happening?
Yesterday AANP learned that FDA staff are recommending to ban compounded glutathione. We have a small window to reverse their position, and we need your help.
The Pharmacy Compounding Advisory Committee (PCAC) - the committee that advises the FDA on this matter - will meet on June 8, 2022, to discuss whether to continue allowing glutathione to be compounded.
We have until TOMORROW, May 24, to provide testimonials to PCAC and show the FDA that banning compounded glutathione is harmful.
If we don't act in time, you and your patients will lose access to compounded glutathione.
PCAC will listen to testimonies, review comments, and consider the FDA staff's recommendations before voting on whether glutathione can or cannot continue to be compounded.
Important: PCAC will only be reviewing the compounded forms of glutathione, not just the ingredient as a dietary supplement.
How can you help?
We are asking providers and patients to submit their stories on compounded glutathione.
Action Needed by May 24th:
If you are a provider who prescribes compounded glutathione, we need you to submit comments to the FDA docket answering these two questions:
- For what condition(s) do you prescribe compounded glutathione? Explain the clinical efficacy and benefits that patients experience from compounded glutathione. Focus on the safety of usage, success stories, how many patients a year utilize it, route of administration (oral, IV, other), etc.
- Have you experienced any adverse effects from compounded glutathione that required therapy to stop? If so, what happened and how often?
Additionally, please forward the link below to your patients!
If you are a patient who utilizes compounded glutathione, please submit comments to the FDA docket on how you have personally benefited from compounded glutathione.
